Consano Bio Receives FDA Investigational New Drug Clearance to Expand the C-1101 Chronic Sciatica Clinical Development Program into the United States

RegulatoryapprovedC-1101Positive

AI Analysis

Summary

Consano Bio received FDA IND clearance for C-1101, a potential first-in-class, disease-modifying, non-opioid therapy for chronic sciatica, enabling expansion of clinical development into the United States.

Clinical Trial Data

Outcome Details

FDA Investigational New Drug (IND) clearance received

Importance:7/10

Sentiment:

0.85

IND clearancefirst-in-classnon-opioiddisease-modifyingchronic painUS expansion

Related Companies

$TRAX

Read the original article

Published by PR Newswire Pharma on July 20, 2026 12:10 PM

Read Original